Adhera Therapeutics (OTCMKTS:ATRX) versus Cadrenal Therapeutics (NASDAQ:CVKD) Financial Review

Adhera Therapeutics (OTCMKTS:ATRX) and Cadrenal Therapeutics (NASDAQ:CVKD) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, earnings, dividends, profitability, valuation and risk.

Earnings and Valuation

This table compares Adhera Therapeutics and Cadrenal Therapeutics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adhera Therapeutics	N/A	N/A	N/A	($1.13)	0.00
Cadrenal Therapeutics	N/A	N/A	-$13.24 million	($5.63)	-0.74

Cadrenal Therapeutics is trading at a lower price-to-earnings ratio than Adhera Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Adhera Therapeutics and Cadrenal Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Adhera Therapeutics	N/A	N/A	N/A
Cadrenal Therapeutics	N/A	-411.03%	-275.61%

Volatility and Risk

Adhera Therapeutics has a beta of 11.38, suggesting that its stock price is 1,038% more volatile than the S&P 500. Comparatively, Cadrenal Therapeutics has a beta of 1.59, suggesting that its stock price is 59% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Adhera Therapeutics and Cadrenal Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adhera Therapeutics	0	0	0	0	0.00
Cadrenal Therapeutics	1	0	1	0	2.00

Cadrenal Therapeutics has a consensus target price of $13.00, indicating a potential upside of 210.26%. Given Cadrenal Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Cadrenal Therapeutics is more favorable than Adhera Therapeutics.

Institutional and Insider Ownership

7.9% of Cadrenal Therapeutics shares are held by institutional investors. 28.2% of Adhera Therapeutics shares are held by insiders. Comparatively, 26.1% of Cadrenal Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Adhera Therapeutics beats Cadrenal Therapeutics on 6 of the 10 factors compared between the two stocks.

About Adhera Therapeutics

Adhera Therapeutics, Inc., a biotech company, focuses on the discovery, development, and commercialization of small molecule drugs. The company is developing MLR-1019 for the treatment of Parkinson's disease; and MLR -1023 to treat Type 1 diabetes. The company was formerly known as Marina Biotech, Inc. and changed its name to Adhera Therapeutics, Inc. in October 2018. Adhera Therapeutics, Inc. is based in Baton Rouge, Louisiana.

About Cadrenal Therapeutics

Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc. was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.